Population Genomic Screening and Improved Lipid Management in Patients With Familial Hypercholesterolemia.
Nov 5, 2025DOI: 10.1161/circgen.125.005206Journal ArticleAHA
Written by: Matthew E LevyKelly M Schiabor BarrettMegan N BettsDavid KannAlexandre BolzeBasil KhuderNatalie TelisLisa M McEwenAmy C SturmChad Haldeman-EnglertJeremy CauwelsDouglas StollerC Anwar A ChahalChristopher N ChapmanAshley A WaringDouglas A OlsonJoseph J GrzymskiNicole L WashingtonWilliam LeeElizabeth T CirulliCatherine Hajek
The data that support the findings of this study are available on reasonable request to the corresponding author from qualified researchers and with permission of the Helix Research Network Steering Committee and Helix.As part of the Helix Research Network, adult patients across 9 health systems participated in a population genomics screening program.15 The participating protocols are DNA answers (St. Luke’s University Health Network, Pennsylvania), GeneConnect (Cone Health, North Carolina), the Genetic Insights Project (Nebraska Medicine), the Healthy Nevada Project (Renown Health, Nevada), ImagineYou (Sanford Health, Upper Midwest), In Our DNA SC (Medical University of South Carolina), myGenetics (HealthPartners, Minnesota), Ohio State Genomic Health (The Ohio State University Wexner Medical Center), and The Gene Health Project (WellSpan Health, Pennsylvania).Each health system is committed to recruiting at least 100 000 participants over a 4 to 5-year period, with the program offered free of charge to all participants. Health systems recruited both patients and community members through various marketing campaigns and communications (including electronic health record [EHR] messages, printed collateral, and digital marketing). Before consent, participants received education about the program’s benefits, including screening for genetic risk factors for Centers for Disease Control and Prevention Tier 1 conditions, how the program works, data security, and the value of participating in research. There were no inclusion or exclusion criteria pertaining to FH or other diagnoses related to FH.Participants provided saliva or blood samples that underwent Exome+Ⓡ sequencing at Helix for subsequent evaluation of pathogenic/likely pathogenic (P/LP) variants for Centers for Disease Control and Prevention Tier 1 genetic conditions, as previously described.10,17 Individuals with a positive screening result for 1 of the conditions, including FH, were offered no-cost genetic counseling through their health system. The health system’s study team initiated outreach to facilitate results disclosure, and genetic counselors discussed the implications of the positive test result with patients, including potential impacts on family members and options for family variant testing. Results were integrated into participants’ EHRs through HL7 interfaces established with each health system partner. Helix delivered both discrete variant results and embedded PDF reports to the health system EHRs, making the genomic findings accessible to providers as part of the patient’s medical record and laboratory results. In cases where initial contact attempts were unsuccessful, a certified letter containing a clinical action plan was sent to the participant. Following result disclosure and referral to genetic counseling, subsequent clinical management for FH followed guideline-directed care using new or existing clinical workflows at each health system. The initial program implementation included collaborative design of downstream clinical workflows with clinicians at each participating site to ensure appropriate patient management.
For research purposes, longitudinal EHR data were retrospectively collected for participating patients and transformed into the Observational Medical Outcomes Partnership Common Data Model version 5.4.18 Study protocols were reviewed and approved by their respective Institutional Review Boards (projects 956068-12 and 21143). All participants provided written informed consent before participation, and all data used for research were deidentified.
Variant interpretation for APOB and PCSK9 was limited to specific, well-established pathogenic variants for FH (Supplemental Data File 1). Gene-level variant interpretation for LDLR was completed for the entire Helix Research Network cohort (N=228 602) using a 2-step approach. A total of 4346 variants were annotated and interpreted. First, a variant was considered either pathogenic (P/LP) or benign/likely benign if it had a known and well-established clinical pathogenic or benign interpretation (ie, no variant of uncertain significance or conflicting interpretations present in ClinVar across high-volume laboratories, using search strings [ClinGen, Quest, Sema4, Natera, Invitae, All of Us, Baylor, GeneDx, Ambry, LapCorp, Color, Myriad, Brigham] and a P/LP or benign/likely benign interpretation by the FH Variant Curation Expert Panel). For all remaining variants, the American College of Medical Genetics and Genomics and the Association for Molecular Pathology variant interpretations were completed programmatically following the gene-specific scoring recommendations from the FH Variant Curation Expert Panel.19 The following criteria were assessed: PVS1, PS1, PS3Supporting, PS4, PM1, PM2, PM5, PP3, BA1, BS1, and BP4 (Figure S1). All variants seen in the Helix Research Network, relevant annotations, scoring by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology data category, and resulting interpretation based off of point totals (pathogenic [>5], higher scoring variant of uncertain significance [3–5], lower scoring variant of uncertain significance [−1 to 2], benign [<−1]) are available in Supplemental Data File 1. Variant annotations were made based on the Matched Annotation from NCBI and EMBL-EBI transcript for LDLR (NM000527.5) and leveraged the following tools: VEP-104, GnomADv4, REVEL, SpliceAI, and the ClinVar database (accessed: 03/10/2025). For the American College of Medical Genetics and Genomics and the Association for Molecular Pathology criterion PS4, data were obtained from systematic variant-level association tests calculated with Regenie20 using inverse-rank normalized LDL-C levels from the UK Biobank cohort (measurement from baseline assessment) and All of Us cohort (median of available measurements), with age, statin use, body mass index, and sex included as a covariates. The PS4 criterion was met if the effect was >0.5 (chosen to match the average effect size of loss-of-function LDLR variants21), the lower limit of the 95% CI was >0.25, and there were >15 carriers in the UK Biobank and All of Us cohorts. Final interpretations were reviewed by a clinical interpretation scientist.
For this analysis, we evaluated multiple EHR-based clinical outcomes within up to 3 years postscreening among patients identified to have an FH-associated P/LP variant. We limited the analysis to those with ≥6 months of both retrospective and prospective data pre- and postgenetic screening, respectively. The date that biospecimens were received by Helix’s laboratory was used as the screening date. First, we evaluated whether patients received a documented diagnosis code for FH (Systematized Nomenclature of Medicine Clinical Term 398036000 or International Classification of Diseases, Tenth Revision, Clinical Modification E78.01). Second, we assessed whether patients received new or modified prescriptions for LDL-lowering therapies, including statins, ezetimibe, PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors, bile acid sequestrant, inclisiran, and bempedoic acid. Statins were classified as low-, moderate-, or high-intensity based on the statin type and dosage according to American Heart Association guidelines.6 Third, we computed changes in serum LDL-C concentrations, comparing each follow-up LDL-C result to the most recent LDL-C result prescreening (within up to 1 year earlier) or, alternatively, to the earliest LDL-C result through up to 60 days postscreening (considered the baseline value, as available, in instances with no result in the 60 days before screening). Continuous differences as well as proportions of patients achieving targets of <70 mg/dL and ≥50% reductions were calculated. The Observational Medical Outcomes Partnership Common Data Model concept sets used to define LDL-lowering agents and EHR-based diagnosis measures are available in Supplemental Data File 2.
Patients’ demographic and clinical characteristics were compared between participants identified to have an FH-associated P/LP variant and those in the broader Helix Research Network. The proportions with new or modified LDL-lowering therapies postscreening were compared between patients with and without documentation of a clinical FH diagnosis code using χ2 tests. Rates of treatment with new or modified LDL-lowering agents by month since screening were also compared between patients with positive versus negative FH screening results, with monthly proportions calculated among patients with available follow-up for the full month’s duration (and with no new or modified therapy having already occurred in an earlier month). Additionally, proportions achieving LDL-C targets and mean maximum changes in LDL-C were compared between patients with and without therapeutic changes using χ2 testing and t tests. P<0.05 indicated statistical significance. Analyses were performed using R software, version 4.2.3.
Results
Within the Helix Research Network, a cohort of 228 602 adults underwent screening for FH and other Centers for Disease Control and Prevention Tier 1 genetic conditions between January 2017 and February 2025, with 52.7% of them having occurred during 2024 or 2025. Overall, 1155 individuals (0.51% or ≈1 in 198) were found to carry a P/LP variant linked to FH. The majority of those patients with FH had a P/LP variant in LDLR (850 of 1155, or 73.6%), while 292 (25.3%) had a P/LP variant in APOB (with the variant p.Arg3527Gln accounting for 91.1% of these) and 13 (1.1%) had a P/LP variant in PCSK9. All patients with FH were heterozygotes, with the sole exception of 1 person with a homozygous LDLR variant. There were no additional detections of homozygous FH or compound heterozygous FH, and there were no patients with a homozygous or compound heterozygous LDLRAP1 variant.
Out of the 1155 patients with FH, EHR data were available for 1087 (94.1%). Among these, 622 patients (57.2%) had medical visit(s) both ≥6 months before and after their genetic screening (as of the dates of data extraction), and thus qualified for inclusion in this analysis.
Similar to the broader network, the mean age of patients with FH was 51 years, and 74.3% were female (Table). The mean body mass index was 29.6 kg/m2, 38.1% had a hypertension diagnosis, and 13.8% had a type 2 diabetes diagnosis. Compared with participants without an FH-associated P/LP variant, those with a P/LP variant had higher mean serum concentrations of LDL-C based on both the most recent prescreening measurement (136 versus 105 mg/dL) and the highest historical measurement (186 mg/dL versus 125 mg/dL). Patients with FH were more likely than those without FH to have been previously treated with an LDL-lowering agent (57.2% versus 26.7%) and to have a prior coronary artery disease (CAD) diagnosis (17.2% versus 7.4%). Only 25.2% of patients with FH had LDL-C<100 mg/dL before screening (61.1% of whom had received LDL-lowering therapy in the prior year), and fewer (7.8%) had LDL-C<70 mg/dL (not shown).
Characteristics of Helix Research Network Participants With and Without an FH-Associated P/LP Variant
The majority of patients with an FH-associated P/LP variant (84.2%) did not have a prior clinical diagnosis of FH documented in the EHR, although 77.7% had been diagnosed with general hyperlipidemia. Those with a prior clinical FH diagnosis were more likely than those without the diagnosis to have used an LDL-lowering agent within the previous year (62.2% versus 33.2%, P<0.001; Figure 1A). When stratifying by baseline CAD diagnosis status, this pattern was observed among patients without CAD (60.5% versus 28.0%; P<0.001), but not among those with CAD, who were largely treated irrespective of prior FH clinical diagnosis status (68.2% versus 60.0%; P=0.65; Figure S2A and S2B).
Low-density lipoprotein (LDL)-lowering therapy before and after genetic screening, stratified by familial hypercholesterolemia (FH) clinical diagnosis status. FH diagnosis status was defined by the presence or absence of electronic health record documentation of a clinical diagnosis code for FH (Systematized Nomenclature of Medicine Clinical Terms 398036000 or International Classification of Diseases, Tenth Revision, Clinical Modification E78.01). A, Includes all patients. B, Includes patients without a prior FH diagnosis who had no LDL-lowering agent prescriptions in the prior year. C, Includes patients without a prior FH diagnosis who had at least 1 LDL-lowering therapy prescription in the prior year; therapeutic changes include an increase in statin dosage, switching of statin type, or initiation of a statin, ezetimibe, PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor, bile acid sequestrant, inclisiran, or bempedoic acid.
Overall, the most common LDL-lowering agents previously used at any time were statins (95.8% of previously treated patients, including 44.3% with atorvastatin, 43.1% with rosuvastatin, and 7.3% with simvastatin), followed by ezetimibe (38.5%). Among patients with a history of statin use, a majority had most recently used a high-intensity statin (62.5%), followed by moderate-intensity (34.3%) and low-intensity (3.2%) statins. The most recent prescreening LDL-C result was lower among patients with LDL-lowering therapy in the prior year compared with those without therapy (124 mg/dL versus 146 mg/dL, P<0.0001).
Since genetic screening, 241 of 524 patients without a prior diagnosis (46.0%) had a new FH diagnosis subsequently documented in the EHR, after a median of 4.7 months (interquartile range [IQR], 2.6–10.5), whereas 54.0% had no evidence of a new FH diagnosis (after a median total follow-up duration of 21.1 months; IQR, 10.2–41.8). Among all patients, 33.1% received new or modified LDL-lowering therapy in the first year, and 41.8% received new/modified therapy within up to 3 years. However, for patients with a new clinical FH diagnosis code documented in the EHR within the first year postscreening, 56.9% received new or modified lipid-lowering therapy within the same period, compared with 17.0% of those without documentation (P<0.001).
When analyzing only patients with no LDL-lowering agent use in the prior year, those with a new clinical FH diagnosis code within the first year were more likely than those without EHR documentation to be newly prescribed an LDL-lowering agent during that year (58.1% versus 15.0%; P<0.001; Figure 1B). The most common newly prescribed agents were statins (82.4% of patients, of whom 57.0% received a high-intensity statin and 42.4.5% received a moderate-intensity statin), ezetimibe (37.0%), and PCSK9 inhibitors (16.0%; Figure 2A). The median duration to first new therapy was 3.7 months after screening (IQR, 2.5–6.4).
New low-density lipoprotein (LDL)-lowering agents and therapeutic changes stratified by prescreening treatment status. PCSK9 indicates proprotein convertase subtilisin/kexin type 9.
Similarly, among patients with treatment in the prior year, those with the new FH diagnosis code documented were more likely than those without EHR documentation to have a therapeutic change (54.9% versus 21.4%; P<0.001; Figure 1C). The most common therapeutic modifications were starting a PCSK9 inhibitor (29.9%) or ezetimibe (25.3%), switches in statin type (23.0%), and increases in statin dosage (23.0%; Figure 2B). Differences further stratified by baseline CAD diagnosis status are displayed in Figure S2C through S2F. The median duration to first modified therapy was 4.8 months after screening (IQR, 2.5–6.9).
Additionally, the proportion of patients who had at least 1 endocrinology or cardiology specialty visit within 18 months following genetic screening was higher among FH-positive participants compared with FH-negative participants (37.3% versus 19.5%; P<0.0001; not shown). This pattern persisted when restricting the analysis to patients with LDL-C ≥160 mg/dL (34.4% versus 18.9%; P<0.0001).
When comparing against patients who tested negative for FH-associated P/LP variants, rates of new or modified LDL-lowering prescriptions were higher in FH-positive patients postscreening, including when only comparing patients with LDL-C ≥160 mg/dL (Figure 3). This pattern was consistent when restricting the analysis to patients without a prior CAD diagnosis (Figure S3).
Rates of treatment with new or modified low-density lipoprotein (LDL)-lowering agents by month since screening among patients who tested positive and negative for familial hypercholesterolemia (FH)-associated variants. Proportions of patients with new or modified therapies within each month were calculated among patients with available follow-up for the full month’s duration and without new or modified therapy already having occurred in an earlier month. LDL-C indicates low-density lipoprotein cholesterol.
In terms of temporal changes, patients with FH-positive had higher rates of LDL-lowering prescriptions after screening compared with before screening (Figure S4A and S4C). Among FH-negative patients, prescription rates also increased after screening for those with LDL-C ≥160 mg/dL (Figure S4B), though their rates remained lower than those of patients with FH-positive with similar LDL-C levels, and there was no significant temporal change in prescription rates among FH-negative patients overall (Figure S4D).
Within up to 2 years after screening, 430 patients (69.1%) had ≥1 follow-up LDL-C test performed, compared with 435 (69.9%) with ≥1 test performed within the 2 years before screening (P=0.76). The median number of tests within both the 2 years before and after screening was 1 per person. Among the 187 patients with no testing in the prior 2 years, 83 (44.4%) received LDL-C testing within the subsequent 2 years (or within the available ≥6 months of follow-up). This proportion was higher among patients with the FH diagnosis code documented within the first year (67.9%) compared with those without EHR documentation (34.4%; P<0.001).
Through up to 3 years of postgenetic screening, 486 (78.1%) participants had ≥1 available follow-up LDL-C measurement. During that time, a median of 2 LDL-C measurements were available (IQR, 1–3), with the date of the last measurement having occurred a median of 13.3 months postscreening (IQR, 7.3–23.6). Among those patients, the overall mean maximum reduction in LDL-C was 34 mg/dL, or a 20.6% reduction from baseline. Overall, patients with new or modified therapies within 1 year postscreening had a mean LDL-C reduction of 52 mg/dL, compared with 20 mg/dL in patients with no new/modified therapy (difference=32 mg/dL; P<0.001).
Among patients with no LDL-lowering agent use in the year before screening, patients who newly received LDL-lowering treatment within 1 year postscreening experienced larger maximum LDL-C reductions than those without treatment initiated (mean reductions of 57 mg/dL [33%] versus 17 mg/dL [11%]; P<0.001; Figure 4A and 4C). Among patients who had a record of LDL-lowering treatment in the year before screening, patients with a therapeutic change within the next year also had larger reductions than those without a therapeutic change (mean reductions of 48 mg/dL [32%] versus 22 mg/dL [11%]; P=0.002 and P<0.001; Figure 4B and 4D).
Maximum absolute and percent low-density lipoprotein cholesterol (LDL-C) reductions through up to 3 years postgenetic screening, stratified by treatment status. Patients are included if they had a baseline LDL-C result available (up to 1 year before genetic screening) and at least 1 follow-up LDL-C result. One patient with the baseline LDL-C testing date within 1 to 60 days after screening was excluded because the new treatment occurred before the baseline LDL-C testing date. Violin plots show the probability density of maximum LDL-C reductions, while overlaid box plots display the median, interquartile range (IQR), and extrema. Whiskers extend to the most extreme data points within 1.5 times the IQR from the box edges.
Absolute reductions in LDL-C were larger in patients with higher baseline LDL-C concentrations (Figure 5). Notably, the variability in these reductions also increased with higher baseline LDL-C concentrations. However, within each baseline LDL-C category, differences in LDL-C changes largely persisted when comparing patients who did and did not receive new or modified LDL-lowering therapies.
Maximum absolute low-density lipoprotein cholesterol (LDL-C) reductions through up to 3 years postgenetic screening, stratified by prescreening LDL-C concentration. Patients are included if they had a baseline LDL-C result available (up to 1 year before genetic screening) and at least 1 follow-up LDL-C result. One patient with the baseline LDL-C testing date within 1 to 60 days after screening was excluded because the new treatment occurred before the baseline LDL-C testing date. Violin plots show the probability density of maximum LDL-C reductions, while overlaid box plots display the median, interquartile range (IQR), and extrema. Whiskers extend to the most extreme data points within 1.5× the IQR from the box edges.
Individual longitudinal trajectories for changes in LDL-C are displayed in Figure S5. In patients with therapeutic additions or changes, LDL-C reductions were largely persistent throughout the follow-up period. Although average reductions were lower in patients without therapeutic additions/changes, a subset of those patients similarly had persistent reductions.
Among patients with baseline LDL-C ≥70 mg/dL, those with new or modified therapies were also more likely than those without therapeutic additions or changes to achieve either a ≥50% reduction in LDL-C or LDL-C<70 mg/dL (39.3% versus 21.4%, P=0.001; Figure 6). The median time to achievement of this target goal was 8.1 months (IQR, 4.8–12.3), with a median of 67% of all postscreening measurements being below the threshold in this group (IQR, 41%–100%).
Achievement of low-density lipoprotein cholesterol (LDL-C) target goals through up to 3 years postgenetic screening, stratified by treatment status. Patients are included if they had a baseline LDL-C result available (up to 1 year before genetic screening) and at least 1 follow-up LDL-C result. Twenty-nine patients with prescreening LDL-C <70 mg/dL were excluded from this figure. One patient with the baseline LDL-C testing date within 1 to 60 days after screening was excluded because the new treatment occurred before the baseline LDL-C testing date. P=0.001, P<0.001, and P=0.004 for each comparison between patients with vs without new/modified therapy (top, middle, and bottom bars, respectively).
Overall, patients with a prior CAD diagnosis were more likely than those without a CAD diagnosis to achieve either a ≥50% reduction in LDL-C or LDL-C <70 mg/dL (45.8% versus 26.6%; P=0.013). This trend was similarly observed among individuals with new or modified therapies (47.6% versus 37.7%; P=0.54) and those without new or modified therapies (44.4% versus 16.5%; P=0.003; Figure S6).
Discussion
Within a large-scale population genomics program, our results suggest that population screening may have potential for supporting improved lipid management in individuals with FH-associated pathogenic variants. Our study reinforces the significant underdiagnosis of FH in standard clinical practice, as <1 in 6 patients with an FH-associated variant had a prior clinical FH diagnosis, despite more than two-thirds having been previously diagnosed with general hyperlipidemia. Following disclosure of positive FH screening results, we observed a shift in clinical management for many patients who received new or modified lipid-lowering therapies within the subsequent year, with higher rates of therapeutic changes among FH-positive patients compared with FH-negative counterparts. Notably, despite nearly two-thirds of FH-positive patients having a history of LDL-lowering therapy, therapeutic modifications postscreening were associated with substantial LDL-C reductions. The mean reduction in LDL-C among FH-positive patients who experienced therapeutic changes was 52 mg/dL, which approximately corresponds to a 30% estimated reduction in risk of cardiovascular events.22 These findings suggest that accurate FH diagnosis may be important for optimal downstream clinical management.
Because FH is characterized by lifelong high LDL-C levels and subsequent elevated risk of premature cardiovascular events, LDL-C targets are more stringent for individuals with FH than in the general population.6,7 Among patients with prescreening LDL-C ≥70 mg/dL who experienced a therapeutic change postscreening, 39% subsequently achieved an LDL-C target of either <70 mg/dL or at least a 50% reduction within up to 3 years of available follow-up, consistent with potential benefits of genetic risk identification for lipid control. The proportion achieving this target was lower in those with no new/modified therapies, and this trend was observed among patients with and without a prior CAD diagnosis. However, gaps remain in achieving optimal control for all individuals. Although our findings suggest that genomic screening may facilitate more effective intervention, further efforts are needed to close these gaps and optimize long-term treatment strategies.
Surprisingly, only slightly more than half of the patients with an FH-associated variant had subsequent EHR documentation of a clinical diagnostic code for FH (eg, International Classification of Diseases, Tenth Revision, Clinical Modification code E78.01 in the problem list), despite all patients having had 1 or more medical visits at least 6 months after genetic screening. Although the FH diagnosis code was used across all participating health systems, it is possible that some patients had their FH diagnosis documented in other structured (eg, genomic testing indicator) or unstructured (eg, clinical notes) EHR fields that were not available for analysis.
Furthermore, lipid management changes were significantly more common in individuals with new EHR documentation of the FH diagnosis code compared with those without—more than twice as likely among patients already treated in the prior year and nearly 4× as likely among patients not treated in the prior year. Although this association is not necessarily causal, it suggests that formal recognition of FH within the medical record may reflect, or potentially facilitate, more proactive lipid management, including the initiation or intensification of therapy. Previous studies have also demonstrated improved compliance with lipid-lowering medication among patients with a genetically confirmed FH diagnosis.23 Beyond identifying FH-associated variants through genetic screening, it is important that this information be effectively integrated into clinical workflows to drive appropriate therapeutic action. Possible approaches include the development of standardized scripting for new FH diagnoses, automated scheduling with a genetic counselor, creation of a health care maintenance topic driven off of the result (eg, reminding clinicians to order LDL-C and refer to a lipid clinic), and generation of a genomics indicator viewable to both the patient and provider, adding broader visibility to the diagnosis. Moreover, the identification of FH cases through genetic screening enables the implementation of cascade testing among family members.24 This approach can amplify the impact of each FH diagnosis, potentially identifying multiple additional cases within families, enabling early intervention and extending the benefits of population screening.
Even in patients with FH with no therapeutic changes, many experienced persistent reductions in LDL-C levels, which may be related to other management changes. This could include behavioral modifications (eg, diet, exercise), increased health care engagement and LDL-C monitoring, improved medication adherence, weight loss, or reductions in systemic inflammation. Although not expected to be common, it is possible that some patients obtained lipid-lowering therapy from another health system, which could have resulted in underascertainment of lipid-lowering agent records.
Additionally, our study relied on prescription records to define LDL-lowering treatment status, and it was unknown whether patients were fully compliant with prescribed treatment regimens. Our analysis included only carriers with sufficient health care engagement to provide adequate prescreening and postscreening data, which may limit generalizability to less engaged patient populations. Factors, such as variations in laboratory measurements or spontaneous fluctuations in lipid levels over time, may have contributed to measurement error. For this analysis, data on fasting status were not available; however, nonfasting status is less likely to affect LDL-C levels, compared with triglyceride levels. Heterogeneity in standard care procedures, clinical workflows, provider practices, and patient populations across and within participating health systems may have contributed to observed differences in outcomes. Although all participants were offered genetic counseling at no cost, complete data on genetic counseling visits were not available for this analysis, limiting our ability to assess counseling utilization following positive genetic screening results. Although these factors could not be fully characterized in the current study, they represent important considerations in planning future implementations of genomic screening programs.
In summary, our findings suggest that population genomic screening for FH has significant potential for cardiovascular disease prevention, with many patients experiencing lipid management improvements and substantial LDL-C reductions. The more pronounced changes in patients with newly documented FH diagnoses highlight the critical need to integrate genomic results into clinical workflows. Future efforts should focus on optimizing result documentation, enhancing long-term lipid management, and evaluating cardiovascular outcomes to maximize the benefits of genomic screening.
Article Information
We acknowledge the Helix bioinformatics and lab teams for their contributions to the production of the exome sequencing pipeline, as well as the research administration team for coordinating the project. We thank all of the participants of DNA Answers, GeneConnect, the Genetic Insights Project, the Healthy Nevada Project, ImagineYou, In Our DNA SC, myGenetics, Ohio State Genomic Health, and The Gene Health Project.
Funding was provided to the Desert Research Institute by the Renown Institute for Health Innovation and the Renown Health Foundation. Funding was provided to DRI by the Nevada Governor’s Office of Economic Development. Funding was provided to the myGenetics program by HealthPartners.
Dr Levy, Dr Schiabor Barrett, Dr Bolze, Mr Khuder, Dr Telis, Dr McEwen, Dr Washington, Dr Lee, Dr Cirulli, and Dr Hajek are employees of Helix. The other authors report no conflicts.
Supplemental Data Files 1 and 2
Figures S1–S6
JC
Dr. Jeremy Cauwels
Internal Medicine · Hospital MedicineSanford Healthjeremycauwels